EyePoint, Inc. - Common Stock (EYPT)
0.2642
-0.0078 (-2.87%)
NASDAQ · Last Trade: Nov 19th, 11:56 PM EST
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages EyePoint, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Lawsuit - EYPT
NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · November 19, 2026
Rosen Law Firm Urges EyePoint, Inc. (NASDAQ: EYPT) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of EyePoint, Inc. (NASDAQ: EYPT) between May 27, 2025, and August 14, 2026. EyePoint describes itself as a company that “develops and commercializes therapeutics to purportedly improve the lives of patients with serious retinal diseases.”
By The Rosen Law Firm, P.A. · Via Business Wire · November 18, 2026
Investor Alert: Robbins LLP Informs Investors of the EyePoint, Inc. Class Action Lawsuit
Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons who purchased or otherwise acquired EyePoint, Inc. (NASDAQ: EYPT) securities between May 27, 2025 and August 14, 2026, both dates inclusive (the “Class Period”). EyePoint develops and commercializes therapeutics to purportedly improve the lives of patients with serious retinal diseases.
By Robbins LLP · Via Business Wire · November 18, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · November 10, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · November 3, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · October 27, 2026
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money
By Levi & Korsinsky, LLP · Via GlobeNewswire · October 26, 2026
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)
DURAVYU’s Phase 3 LUCIA trial missed its primary endpoint and EYPT shares lost nearly 80% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have legal rights arising from those losses
By Levi & Korsinsky, LLP · Via GlobeNewswire · October 22, 2026
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
NEW YORK CITY, NY / ACCESS Newswire / October 21, 2026 / EyePoint Pharmaceuticals (NASDAQ:EYPT) shares fell roughly 80% after the Company reported that its Phase 3 LUCIA trial of DURAVYU in wet age-related macular degeneration missed its primary endpoint of non-inferiority to on-label aflibercept. If you held EYPT shares when that result hit, your losses may be part of an active investigation. Investors who suffered losses are encouraged to submit their EYPT loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
By Levi & Korsinsky, LLP · Via ACCESS Newswire · October 21, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · October 6, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 29, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 22, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 15, 2026
Investigation Launched Into EyePoint, Inc., EYPT Investors are Encouraged to Contact KTMC Law Firm
RADNOR, PA - September 9, 2026 (NEWMEDIAWIRE) - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
Via NewMediaWire · September 9, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 8, 2026
INVESTIGATION ALERT: Investigation Launched Into EyePoint, Inc. (EYPT), Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · September 8, 2026
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In EyePoint (EYPT) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · September 2, 2026
EYPT ALERT: Investigation Launched Into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · September 2, 2026
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
By Kirby McInerney LLP · Via Business Wire · September 1, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 1, 2026
Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · September 1, 2026
NASDAQ: EYPT: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into EyePoint, Inc.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 31, 2026
EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EYPT Investors With Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 29, 2026
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or “the Company”) (NASDAQ: EYPT) for violations of the securities laws.
By Schall, Brown & Schwartz LLP · Via Business Wire · August 28, 2026
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
By Kessler Topaz Meltzer & Check, LLP · Via Business Wire · August 26, 2026
